FDA-Approved Medications for Sleep Maintenance Insomnia
For sleep maintenance insomnia specifically, use suvorexant (10-20 mg), doxepin (3-6 mg), eszopiclone (2-3 mg), zolpidem (10 mg), or temazepam (15 mg) as first-line pharmacologic options. 1
Primary FDA-Approved Options for Sleep Maintenance
The 2017 American Academy of Sleep Medicine clinical practice guideline identifies the following FDA-approved medications specifically effective for maintaining sleep throughout the night:
Orexin Receptor Antagonist
- Suvorexant: Specifically recommended for sleep maintenance insomnia at doses of 10,15/20, or 20 mg. This works by blocking wakefulness signals rather than inducing sedation, with no evidence of rebound insomnia or withdrawal 1, 2
Tricyclic Antidepressant
- Doxepin: Low-dose formulation (3-6 mg) specifically targets sleep maintenance through histamine receptor antagonism. This is distinct from higher antidepressant doses 1, 3
Benzodiazepine Receptor Agonists (Z-drugs)
- Eszopiclone: 2-3 mg doses effective for both sleep onset AND sleep maintenance 1
- Zolpidem: 10 mg doses (standard or extended-release formulations) address both sleep onset and maintenance 1
Benzodiazepine
- Temazepam: 15 mg doses effective for both sleep onset and maintenance, though benzodiazepines carry higher risks in elderly patients 1, 3
Important Clinical Considerations
All recommendations are WEAK under GRADE methodology, reflecting the quality of available evidence rather than ineffectiveness. This downgrading occurs due to pharmaceutical funding sources, publication bias risk, limited trial numbers per agent, and data heterogeneity 1.
Newer Agents (Post-2017 Guideline)
Since the 2017 AASM guideline, additional dual orexin receptor antagonists (DORAs) have received FDA approval:
- Lemborexant: Approved for sleep maintenance
- Daridorexant: Newest DORA with ideal 8-hour half-life, demonstrated 12-month efficacy 2, 4
These newer DORAs share suvorexant's mechanism of inhibiting wakefulness rather than inducing sedation, with favorable safety profiles including no abuse potential 2.
Medications to Avoid
Do NOT use the following for sleep maintenance despite common off-label prescribing:
- Trazodone: Negative recommendation despite widespread use; carries significant risks without proven efficacy 1
- Diphenhydramine: Not recommended; causes next-day sedation, particularly problematic in elderly 1, 3
- Melatonin: Not effective for sleep maintenance insomnia 1
- Tiagabine: Explicitly not recommended; ineffective and should not be utilized 1, 3
Clinical Decision Algorithm
Step 1: Determine if sleep maintenance is the primary complaint (frequent awakenings, early morning awakening, inability to return to sleep)
Step 2: Select agent based on patient factors:
- Younger adults without comorbidities: Suvorexant, eszopiclone, or zolpidem extended-release
- Elderly patients: Low-dose doxepin (3-6 mg) or suvorexant preferred due to better safety profile; avoid benzodiazepines 3
- Patients concerned about dependence: Suvorexant, lemborexant, or daridorexant (no abuse potential) 2
- Middle-of-night awakenings: Low-dose zolpidem sublingual or zaleplon for as-needed use 3
Step 3: Duration considerations
- FDA approves these medications without duration restrictions since 2005, recognizing chronic insomnia often lasts >2 years 5
- However, use shared decision-making regarding long-term use, as observational data suggest potential risks (dementia, falls, fractures) 6
- If insomnia persists beyond 7-10 days of treatment, further evaluation is warranted 6
Critical Safety Warnings
The FDA mandates warnings about "sleep-related complex behaviors" (sleep-driving, sleep-eating) for ALL hypnotics 5. Women require lower zolpidem doses due to higher morning drug levels causing daytime impairment 5.
Benzodiazepines should not be used routinely due to risks of cognitive impairment, falls, and dependence, particularly in elderly populations 3.